Major investment to support tech and life sciences sectors in Europe
Claret Capital Partners has closed its fourth European Growth Capital Fund at €575 million—exceeding its €500 million target. This fund will focus on growth debt investments across technology, life sciences, and impact-driven companies in Europe.
The firm has already deployed 32% of its capital to support over 27 companies, including notable names such as Billie and Cinclus Pharma. With contributions from various institutional investors, Claret aims to address the increasing demand for flexible, non-dilutive capital amidst challenging equity market conditions.
The final close of the fund signifies strong support from Claret's limited partners and showcases a robust pipeline of investment opportunities as global markets evolve.
For more information, visit the original article here.
